Loading
Anyone building a new test for HER2, PD-L1 or tumour DNA should be able to check it against the same public reference set. Today each developer validates on private data nobody can inspect.
Analytical validation of biomarker tests uses proprietary sample sets, making performance claims incomparable. A public repository of consensus-annotated cases per biomarker (whole slide images with multi-pathologist scores, sequencing data with orthogonally confirmed variants, plasma samples with defined variant allele fractions) would allow head-to-head benchmarking and independent verification of any test or algorithm, including AI-based ones.
Shares Version control and locked reference sets for AI algorithms used as companion diagnostics, One digital PD-L1 scale that maps across all the competing assays, AI that is built but not validated or deployed, Digital pathology & AI.
Shares An annual blinded shoot-out for liquid biopsy tests, Biomarkers are not validated or standardised, Liquid biopsy (ctDNA).
Shares Version control and locked reference sets for AI algorithms used as companion diagnostics, One digital PD-L1 scale that maps across all the competing assays, AI that is built but not validated or deployed, Digital pathology & AI.
Shares Version control and locked reference sets for AI algorithms used as companion diagnostics, Biomarkers are not validated or standardised.
Shares One digital PD-L1 scale that maps across all the competing assays, Biomarkers are not validated or standardised.
Shares AI that is built but not validated or deployed, Digital pathology & AI.
Shares AI that is built but not validated or deployed, Digital pathology & AI.